<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14776">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02914535</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-418-3899</org_study_id>
    <secondary_id>2016-002765-58</secondary_id>
    <nct_id>NCT02914535</nct_id>
  </id_info>
  <brief_title>Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis</brief_title>
  <acronym>SELECTIONLTE</acronym>
  <official_title>A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects With Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Galapagos NV</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to observe the long-term safety of filgotinib in
      adults who have completed or met protocol specified efficacy discontinuation criteria in a
      prior Gilead-sponsored filgotinib treatment study in ulcerative colitis (UC).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2017</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Safety Profile of Filgotinib Evaluated by Proportion of Participants Experiencing Adverse Events and Abnormal Clinical Laboratory Tests</measure>
    <time_frame>Up to 144 weeks plus 30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Components of Mayo Clinic Score (MCS)</measure>
    <time_frame>Baseline and up to 144 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Filgotinib Dose A (blinded dosing)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Filgotinib dose A + placebo to match dose B for up to 144 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Filgotinib Dose B (blinded dosing)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Filgotinib dose B + placebo to match dose A for up to 144 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (blinded dosing)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for up to 144 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Filgotinib Dose A (open-label)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Filgotinib dose A for up to 144 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Filgotinib Dose B (open-label)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Filgotinib dose B for up to 144 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgotinib</intervention_name>
    <description>Tablet(s) administered orally once daily</description>
    <arm_group_label>Filgotinib Dose A (blinded dosing)</arm_group_label>
    <arm_group_label>Filgotinib Dose B (blinded dosing)</arm_group_label>
    <arm_group_label>Filgotinib Dose A (open-label)</arm_group_label>
    <arm_group_label>Filgotinib Dose B (open-label)</arm_group_label>
    <other_name>GS-6034</other_name>
    <other_name>GLPG0634</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Table(s) administered orally once daily</description>
    <arm_group_label>Filgotinib Dose A (blinded dosing)</arm_group_label>
    <arm_group_label>Filgotinib Dose B (blinded dosing)</arm_group_label>
    <arm_group_label>Placebo (blinded dosing)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Must have the ability to understand and sign a written informed consent form (ICF),
             which must be obtained prior to initiation of study procedures associated with this
             trial

          -  Must have completed all required procedures or met protocol specified efficacy
             discontinuation criteria in a prior Gilead-sponsored filgotinib treatment study for
             UC

          -  Females of childbearing potential must have a negative pregnancy test at Day 1

          -  Male and female individuals of childbearing potential who engage in heterosexual
             intercourse must agree to use protocol specified method(s) of contraception as
             described in the protocol for the duration described

          -  Willingness to refrain from live or attenuated vaccines during the study and for 12
             weeks after last dose of study drug

        Key Exclusion Criteria:

          -  Known hypersensitivity to the study drug

          -  Any chronic medical condition (including, but not limited to, cardiac or pulmonary
             disease, alcohol or drug abuse) that, in the opinion of the Investigator, would make
             the subject unsuitable for the study or would prevent compliance with the study
             protocol

          -  Males or females of reproductive potential who are unwilling to abide by
             protocol-specified contraceptive methods as defined in the participants

          -  Use of prohibited medications as outlined in the protocol

        NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Study Team</last_name>
    <email>418-3899study@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Digestive Health Specialists Of The Southeast</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ocean Blue Medical Research Center, Inc</name>
      <address>
        <city>Miami Springs</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Pharma CR, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33147</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Group of Naples</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Delta Research Partners</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meritus Center for Clinical Research</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21742</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute of Michigan, LLC</name>
      <address>
        <city>Chesterfield</city>
        <state>Michigan</state>
        <zip>48047</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kansas City Research Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carolina's GI Research LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ClinSearch, LLC</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Center of the MidSouth, P.C.</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Research of America</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Digestive Disease Consultants, San Marcos</name>
      <address>
        <city>San Marcos</city>
        <state>Texas</state>
        <zip>78666</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Digestive Disease Consultants</name>
      <address>
        <city>Southlake</city>
        <state>Texas</state>
        <zip>76092</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charlottesville Medical Research</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emeritas Research Group</name>
      <address>
        <city>Lansdowne</city>
        <state>Virginia</state>
        <zip>20176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Digestive and Liver Disease Specialists</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Allegiance Research Specialists, LLC</name>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <zip>53225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Capital and Coast District Health Board</name>
      <address>
        <city>Newton</city>
        <zip>WE 6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>H-T Centrum Medyczne</name>
      <address>
        <city>Tychy</city>
        <zip>43-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nzoz Vivamed</name>
      <address>
        <city>Warsaw</city>
        <zip>03-003</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Oporow</name>
      <address>
        <city>Wroclaw</city>
        <zip>52-416</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich University Hospital Nhs Foundation Trust</name>
      <address>
        <city>Norwich</city>
        <state>Norfolk</state>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fairfield General Hospital</name>
      <address>
        <city>Bury</city>
        <zip>BL9-7TD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth University Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Glasgow Royal Infirmary</name>
      <address>
        <city>Glasgow</city>
        <zip>G52 3NQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Whiston Hospital - St Helens And Knowsley Teaching Hospitals Nhs Trust</name>
      <address>
        <city>Prescot</city>
        <zip>L35 5DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 31, 2017</lastchanged_date>
  <firstreceived_date>September 22, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Colitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
